Principal investigators and laboratory researchers seeking to buy CJC-1295 and Ipamorelin require analytical-grade, highly purified compounds backed by verifiable lot-specific documentation. PX1 Research supplies premium growth hormone secretagogue research formulations engineered strictly for in vitro assays and preclinical animal models. Every batch is manufactured in USA-based, GMP-compliant facilities and thoroughly tested to ensure rigorous experimental reproducibility.
Principal investigators and laboratory researchers seeking to buy CJC-1295 and Ipamorelin require analytical-grade, highly purified compounds backed by verifiable lot-specific documentation. PX1 Research supplies premium growth hormone secretagogue research formulations engineered strictly for in vitro assays and preclinical animal models. Every batch is manufactured in USA-based, GMP-compliant facilities and thoroughly tested to ensure rigorous experimental reproducibility.
When qualified institutions buy CJC-1295 and Ipamorelin for laboratory research, they are acquiring two distinct synthetic peptides designed to co-stimulate the anterior pituitary gland via complementary signaling cascades. CJC-1295 acts as a synthetic growth-hormone-releasing hormone (GHRH) analog, while Ipamorelin functions as a selective ghrelin/growth hormone secretagogue receptor (GHS-R) agonist. Together, these compounds are evaluated in preclinical models to explore pulsatile endogenous growth hormone elevation and downstream insulin-like growth factor 1 (IGF-1) expression.
PX1 Research delivers analytical-grade cjc-1295 ipamorelin blend vials optimized for molecular biology, receptor binding, and tissue repair assays. Every lot undergoes rigorous testing at an accredited ISO 17025 laboratory using reverse-phase high-performance liquid chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS) to guarantee chemical identity and a minimum purity of 99%. All products are intended solely for laboratory research use and are not for human or veterinary administration.
To browse our complete portfolio of GHRH analogs, somatotrophic secretagogues, and custom peptides, researchers can explore our full catalog of all peptides or register for institutional access through our wholesale research accounts.
The scientific rationale for combining CJC-1295 and Ipamorelin lies in their orthogonal mechanisms of action within the hypothalamic-pituitary-somatotropic axis. CJC-1295 is a modified 29-amino-acid peptide (Growth Hormone Releasing Factor 1-29 amide) optimized for extended plasma half-life. As a GHRH receptor agonist, CJC-1295 binds to GHRH receptors on pituitary somatotrophs, triggering the adenylate cyclase/cAMP signal transduction pathway. Preclinical literature demonstrates that CJC-1295 studied as a long-acting growth-hormone-releasing hormone sustains GH and downstream IGF-1 levels for tissue repair research.
Conversely, Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that selectively targets the growth hormone secretagogue receptor 1a (GHS-R1a), mimicking endogenous ghrelin. Activation of GHS-R1a initiates a phospholipase C-dependent intracellular calcium release, which induces exocytosis of pre-stored GH vesicles from somatotroph cells. Unlike non-selective ghrelin mimetics, in vitro and rodent assays show that Ipamorelin stimulates GH release without evoking significant increases in adrenocorticotropic hormone (ACTH), cortisol, or prolactin.
When evaluated concurrently in preclinical models, these two peptides demonstrate dual signal amplification. The activation of both GHRH and GHS-R receptors induces a physiological release of endogenous growth hormone that exceeds the additive effect of either peptide administered in isolation. Researchers interested in exploring these synergistic cascades further can review our technical guide on cjc 1295 ipamorelin synergy mechanism.
Preclinical investigations utilizing CJC-1295 and Ipamorelin focus predominantly on cellular repair mechanisms, protein synthesis, and metabolic homeostasis. In rodent models of musculoskeletal injury, sustained elevation of serum IGF-1 via GHRH analogs accelerates tendon-to-bone healing, enhances osteoblast proliferation, and increases collagen type I mRNA expression. These bio-assays provide insight into how sustained somatotropic signaling impacts connective tissue recovery following mechanical strain.
In vitro studies examining skeletal muscle myoblasts indicate that combined secretagogue exposure upregulates phosphorylation of mammalian target of rapamycin (mTOR) and its downstream effectors, p70S6K and 4E-BP1. This pathway activation enhances myofibrillar protein synthesis and cell cross-sectional area in cultured tissue. Concurrently, rodent metabolic studies suggest that elevated circulating growth hormone alters lipid partitioning, promoting lipolysis in white adipose tissue via hormone-sensitive lipase activation while preserving lean mass during caloric restriction protocols.
Additional research explores the neuroprotective and cardiovascular effects of GHS-R activation. Rodent stroke and ischemia models demonstrate that ghrelin receptor activation by Ipamorelin suppresses pro-inflammatory cytokines such as TNF-alpha and IL-1 beta while mitigating oxidative stress in neuronal tissue. For comparative data on cellular protection mechanisms across different peptide families, consult our review on bpc 157 preclinical review.
Selecting the appropriate secretagogue combination for research requires analyzing receptor selectivity, half-life, and non-target endocrine responses. The CJC-1295 and Ipamorelin combination offers distinct analytical advantages when compared to traditional GHRH analogs and first-generation growth hormone releasing peptides (GHRPs).
For example, Sermorelin is a native 29-amino-acid GHRH fragment with a rapid enzymatic clearance rate (half-life of approximately 10–12 minutes in vivo), requiring frequent dosing in animal models to maintain elevated somatotropic signaling. In contrast, CJC-1295 (without DAC) exhibits four substituted amino acids that confer resistance to dipeptidyl peptidase-IV (DPP-IV) degradation, significantly extending its biological activity. When evaluating ghrelin mimetics, earlier generation peptides such as GHRP-2 and GHRP-6 demonstrate potent GH release but frequently cause transient spikes in cortisol, ACTH, and serum aldosterone due to cross-reactivity with ghrelin-adjacent receptors. Ipamorelin maintains strict receptor selectivity for GHS-R1a, isolating somatotropic pathways from glucocorticoid background noise in controlled assays.
To ensure internal validity and repeatability across experimental sets, researchers must verify the chemical integrity of their peptide reagents. Substandard or unverified peptides introduce confounding variables, such as truncated sequence impurities, residual synthesis solvents, or bacterial endotoxins that can disrupt cellular assays and invalidate preclinical data.
PX1 Research establishes the industry standard for quality verification by providing lot-specific Certificates of Analysis (COA) for every batch. Our analytical verification includes:
• Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Quantifies chemical purity, ensuring every lot meets or exceeds a >99% threshold. • Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular weight and amino acid sequence identity against theoretical mass specifications. • Chromogenic LAL Endotoxin Testing: Measures bacterial endotoxin levels to guarantee products contain <0.01 EU/mg, protecting cell cultures and animal models from inflammatory contamination. • Moisture and Solvent Residual Analysis: Verifies thorough lyophilization and residual trifluoroacetic acid (TFA) removal.
All manufacturing is performed within state-of-the-art, GMP-compliant facilities in the USA. Samples are routinely submitted to independent, third-party ISO 17025 accredited analytical laboratories. Principal investigators can inspect chemical documentation directly via our research library hub.
Lyophilized CJC-1295 and Ipamorelin must be reconstituted under sterile laboratory conditions prior to introduction into assay media or animal model protocols. Proper handling prevents physical aggregation, chemical cleavage, and bacterial contamination.
For most cell culture and biochemical applications, standard reconstituted solutions utilize sterile 0.9% Bacteriostatic Water (containing 0.9% benzyl alcohol as an antimicrobial preservative) or sterile 0.9% Sodium Chloride injection solution. When working with sensitive cell culture models where benzyl alcohol may induce cytotoxicity, sterile 0.01M Phosphate-Buffered Saline (PBS, pH 7.4) or sterile Water for Injection (WFI) is recommended.
Reconstitution should be executed by slowly introducing the diluent down the glass inner wall of the vial using a sterile syringe, allowing the solvent to saturate the lyophilized cake. Severe mechanical agitation or vigorous shaking must be avoided, as shear forces can disrupt the tertiary structure and induce peptide aggregation. The vial should be gently swirled until the solid material completely dissolves into a clear, colorless solution.
Lyophilized peptide formulations exhibit high thermodynamic stability when stored at appropriate temperatures, but exposure to heat, light, and ambient moisture causes rapid degradation.
Lyophilized Vials: Store at -20°C to -80°C in a desiccated environment protected from light exposure. Under frozen conditions (-20°C), lyophilized CJC-1295 and Ipamorelin remain stable for 24 months. If short-term storage (under 30 days) is required, unopened vials may be maintained at refrigerated temperatures (2°C to 8°C).
Reconstituted Solutions: Once reconstituted into liquid phase, peptides become susceptible to hydrolysis and oxidation. Reconstituted aliquots must be stored at 2°C to 8°C and utilized within 21 to 28 days if prepared with bacteriostatic water. For extended experimental timelines, reconstituted solutions should be aliquoted into single-use polypropylene tubes and stored at -80°C to avoid repeated freeze-thaw cycles, which degrade peptide potency.
Research integrity relies heavily on supply chain transparency and rapid reagent procurement. PX1 Research operates fully within the USA, eliminating international shipping delays, customs holds, and untraceable overseas cold-chain breakdowns.
Orders placed before standard cutoff times ship same-day, Monday through Friday, directly from our dual logistics hubs located in California and Arizona. Fast domestic transit minimizes temperature fluctuations during transit, safeguarding peptide integrity upon delivery. Institutional procurement offices managing bulk research requirements or specialized batch orders can learn more on our wholesale procurement page or contact our technical support team for customized lot reservations.
What is the primary scientific rationale for combining CJC-1295 and Ipamorelin in research?
CJC-1295 acts as a long-acting GHRH analog while Ipamorelin functions as a selective ghrelin/GHS-R agonist. Preclinical literature indicates that co-activation of GHRH and GHS-R receptors produces a synergistic stimulation of endogenous growth hormone release from anterior pituitary somatotrophs, yielding higher serum GH and IGF-1 levels than single-agent administration.
How does PX1 Research verify the purity of CJC-1295 and Ipamorelin blends?
PX1 Research verifies chemical quality using lot-specific Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity exceeding 99%, alongside Electrospray Ionization Mass Spectrometry (ESI-MS) to verify molecular weight. Testing is conducted by independent ISO 17025 accredited laboratories.
Are PX1 Research CJC-1295 and Ipamorelin compounds tested for endotoxins?
Yes. Every production lot undergoes chromogenic LAL testing to ensure bacterial endotoxins remain strictly below <0.01 EU/mg, preventing inflammatory interference in cell assays and preclinical models.
What diluent should be used for reconstituting CJC-1295 and Ipamorelin for lab assays?
Sterile 0.9% Bacteriostatic Water is standard for multi-use laboratory assays requiring microbial inhibition. For cytotoxicity-sensitive cell culture applications, sterile 0.9% Saline or Phosphate-Buffered Saline (PBS) without preservatives is recommended.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with Drug Affinity Complex (DAC) covalently binds to circulating serum albumin, extending its biological half-life to approximately 6–8 days. CJC-1295 without DAC (often termed Modified GRF 1-29) has a shorter half-life of 30 minutes, producing more discrete, physiological pulses of GH release in experimental models.
How should reconstituted CJC-1295 and Ipamorelin be stored?
Reconstituted liquid solutions should be stored at 2°C to 8°C and used within 21–28 days. For longer storage, freeze single-use aliquots at -80°C. Repeated freeze-thaw cycles must be avoided to prevent peptide degradation.
Where are PX1 Research CJC-1295 and Ipamorelin peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and shipped directly from our primary distribution hubs in California and Arizona with same-day shipping on orders placed Monday through Friday.
Are CJC-1295 and Ipamorelin approved for human use or therapeutic administration?
No. CJC-1295 and Ipamorelin sold by PX1 Research are strictly for laboratory research, analytical testing, and preclinical in vitro or animal models. They are strictly not for human, clinical, or veterinary use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.